Triple-negative breast cancer: current perspective on the evolving therapeutic landscape

Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehanna, Joe, Haddad, Fady GH, Eid, Roland, Lambertini, Matteo, Kourie, Hampig Raphael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682754/
https://www.ncbi.nlm.nih.gov/pubmed/31447592
http://dx.doi.org/10.2147/IJWH.S178349
_version_ 1783441944939069440
author Mehanna, Joe
Haddad, Fady GH
Eid, Roland
Lambertini, Matteo
Kourie, Hampig Raphael
author_facet Mehanna, Joe
Haddad, Fady GH
Eid, Roland
Lambertini, Matteo
Kourie, Hampig Raphael
author_sort Mehanna, Joe
collection PubMed
description Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.
format Online
Article
Text
id pubmed-6682754
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66827542019-08-23 Triple-negative breast cancer: current perspective on the evolving therapeutic landscape Mehanna, Joe Haddad, Fady GH Eid, Roland Lambertini, Matteo Kourie, Hampig Raphael Int J Womens Health Review Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy. Dove 2019-07-31 /pmc/articles/PMC6682754/ /pubmed/31447592 http://dx.doi.org/10.2147/IJWH.S178349 Text en © 2019 Mehanna et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mehanna, Joe
Haddad, Fady GH
Eid, Roland
Lambertini, Matteo
Kourie, Hampig Raphael
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
title Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
title_full Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
title_fullStr Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
title_full_unstemmed Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
title_short Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
title_sort triple-negative breast cancer: current perspective on the evolving therapeutic landscape
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682754/
https://www.ncbi.nlm.nih.gov/pubmed/31447592
http://dx.doi.org/10.2147/IJWH.S178349
work_keys_str_mv AT mehannajoe triplenegativebreastcancercurrentperspectiveontheevolvingtherapeuticlandscape
AT haddadfadygh triplenegativebreastcancercurrentperspectiveontheevolvingtherapeuticlandscape
AT eidroland triplenegativebreastcancercurrentperspectiveontheevolvingtherapeuticlandscape
AT lambertinimatteo triplenegativebreastcancercurrentperspectiveontheevolvingtherapeuticlandscape
AT kouriehampigraphael triplenegativebreastcancercurrentperspectiveontheevolvingtherapeuticlandscape

Ejemplares similares